# Medtronic plc. (MDT) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Technology. Price $94.17, market value $120.5 billion.

## Valuation
- **P/E (trailing): 23.2×** (5-yr avg 24.9×, 3-yr avg 23.8×). Medtronic plc. trades at 23.2× trailing earnings, close to its own five-year average of 24.9×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 14.7×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 4.43**. A PEG of 4.43 means the P/E is high relative to expected earnings growth; the price already assumes a lot.
- **Price / sales: 3.2×**. Each dollar of revenue is priced at 3.2×.
- **Price / book: 2.4×**. The shares trade at 2.4× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 12.4×**. Enterprise value is 12.4× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 5.1%** (5-yr avg 4.9%). Free cash flow equals 5.1% of the market value, in line with its five-year average of 4.9%. Above 5% is generally attractive.
- **Earnings yield: 4.3%**. The inverse of the P/E: 4.3% of the price is earned each year.

## Profitability
- **Operating margin: 18.1%**. 18.1% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 13.2%**. 13.2% of each dollar of sales reaches the bottom line.
- **Return on equity: 9.7%**. 9.7% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 10.9%**. Return on all capital, debt included, is 10.9%.
- **Return on assets: 5.6%**. Each dollar of assets produces 5.6% of profit.

## Growth
- **Revenue growth (1 yr): 8.4%** (3-yr 5.2%/yr, 5-yr 3.8%/yr). Revenue grew 8.4% over the last year, against 3.8% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 3.3%** (3-yr 9.8%/yr, 5-yr 7.0%/yr). Earnings per share rose 3.3%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 5.8%/yr**. Free cash flow has compounded at 5.8% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.04**. Debt is 0.04 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Medtronic plc. holds more cash than debt.
- **Altman Z-score: 3.05**. A Z-score of 3.05 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 3.06%** ($2.85 per share, trailing). Medtronic plc. yields 3.06%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 76%** (60% of free cash flow). 76% of earnings goes out as dividends, leaving a thin cushion.
- **Consecutive years of increases: 12**. 12 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 4.4%/yr** (1-yr 1.4%). The dividend has grown 4.4% a year over five years.

## Analyst view
- **Analyst consensus: buy** (25 analysts). 25 analysts cover Medtronic plc.; the consensus is buy, with an average price target of $104.76 (+11% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 4.7%** (YTD -0.3%, 3-mo 16.3%). The shares are up 4.7% over twelve months including dividends.
- **From 52-week high: -11.4%** (28.5% above the low). Trading 11% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 65**. An RSI of 65 is neutral.
- **Beta (1 yr): 0.18** (volatility 23%). Beta of 0.18 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MDT · Page: https://foliofundamentals.com/stocks/mdt

Not investment advice.